Yogen Saunthararajah

Yogen Saunthararajah

Hematology Oncology | Hematology | Oncology

9500 Euclid Avenue
Cleveland, OH 44195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 118 publications

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

Journal: Research square

Published: August 20, 2026

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2026

Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias.

Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias.

Journal: Leukemia & lymphoma

Published: July 25, 2026

H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics.

H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics.

Journal: Science advances

Published: July 10, 2026

Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Journal: Haematologica

Published: January 13, 2026

Epigenetic drug remedies for SCD root cause pathophysiology.

Epigenetic drug remedies for SCD root cause pathophysiology.

Journal: Blood

Published: July 17, 2025

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis.

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis.

Journal: Experimental hematology

Published: May 05, 2025

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesis.

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesis.

Journal: Experimental hematology

Published: May 05, 2025

Combining drugs that bypass p53 to treat TP53-mutated leukemias.

Combining drugs that bypass p53 to treat TP53-mutated leukemias.

Journal: Blood advances

Published: March 31, 2025

PET imaging of hepatocellular carcinoma with [124I]IV-14.

PET imaging of hepatocellular carcinoma with [124I]IV-14.

Journal: EJNMMI research

Published: January 06, 2025

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Journal: Haematologica

Published: December 23, 2024

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Journal: Blood

Published: June 28, 2024

Showing 1-12 of 118

Last Updated: 09/26/2026